PUNE, India, May 18, 2017 /PRNewswire-iReach/ -- Iron is among the vital minerals present in the human body. It is one of the components of hemoglobin, the substance present in red blood cells that carries oxygen throughout the body through blood, and oxygen is further utilized by the cells to produce energy required to perform all the required functions. Therefore, decline in the body's supply of iron can lead to severe problems. The balance of iron in the body primarily is a combined result of three dynamics- intake, losses and metabolic demand.
Complete report on Intravenous (IV) Iron Drugs market spread across 64 pages with providing 3 company Profiles and 33 charts is now available at http://www.marketreportsonline.com/591704.html.
Company Coverage of Intravenous (IV) Iron Drugs Market: Galenica Group, AMAG Pharmaceuticals & Allergan plc.
Intravenous (I.V.) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous (I.V.) drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body.
The report "Global I.V. Iron Drugs Market" provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry, Galenica Group, AMAG Pharmaceuticals and Allergan are being profiled. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.
The key factors driving the growth of I.V. iron drugs market are growing ageing population, growing urbanization, increase in number of dialysis cases, rising healthcare expenditure and increasing life expectancy rate. Some of the noteworthy trends and developments of this industry are paradigm shift from oral iron drugs to intravenous iron drugs and introduction of first generation drugs InFeD and Dexeferrum. However, the expansion of the market is hindered by potential risks of I.V. iron.
Purchase a copy of this "Global I.V. Iron Drugs Market" research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=591704.
Major Points from Table of Contents:
1. I.V. Iron Market - An Overview
1.1 Iron in Human Body: An Introduction
1.2 I.V. Iron Application Areas
1.3 I.V. Iron Applications in Nephrology
1.4 Iron Deficiency - Anemia
1.5 Iron Therapies for Anemia Treatment
2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value
2.2 Global Iron Product Market Forecast by Value
2.3 Global Iron Product Market by Segments
3. Global I.V. Iron Drugs Market Analysis
3.1 Global I.V. Iron Drugs Market by Value
3.2 Global I.V. Iron Drugs Market Forecast by Value
3.3 Global I.V. Iron Drugs Market by Product Category
3.4 Global I.V. Iron Drugs Market Share by Product Category
3.5 Global I.V. Iron Drugs Market Share by Segments
4. Regional Market Analysis
4.1 The US
5. Market Dynamics
5.1 Growth Drivers
5.2 Market Trends
5.3.1 Potential Risks of I.V. Iron
6. Competitive Landscape
6.1 Comparison between Injectafer, Venofer, INFeD and Feraheme
7. Company Profiles
Explore more pharmaceuticals market research as well as other newly published reports by Daedal Research at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html.
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Media Contact: Ritesh Tiwari, MarketReportsOnline, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com